GlassScriptPhysician profile
Linda Narvaez
NPI 1588760508
$7,870.04
in general payments reported to CMS, 2019-2025
40 companies · $733 in 2025
The $733 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,535 · 2020: $1,290 · 2021: $1,940 · 2022: $906 · 2023: $744 · 2024: $722 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,781.73 | 2019-2025 | |
| Gilead Sciences, INC. | $1,282.55 | 2019-2024 | |
| Novo Nordisk INC | $887.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $595.88 | 2019-2025 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $425.34 | 2019-2022 | |
| Lilly USA, LLC | $355.79 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $316.26 | 2024-2025 | |
| Allergan, INC. | $287.40 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $203.82 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.79 | 2022-2024 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $163.32 | 2019-2024 | Otezla, Repatha, Prolia |
| Glaxosmithkline, LLC. | $145.58 | 2021-2025 | Arexvy, Shingrix |
| Ultragenyx Pharmaceutical INC. | $127.92 | 2020-2022 | |
| Exact Sciences Corporation | $120.92 | 2023-2025 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $112.47 | 2022-2024 | Tirosint, Tirosint, Licart |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Narvaez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.